Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elisabeth Schnoy

Showing results (1-10 of 35) with videos related to

Pageof 4
Sort By:
Innere Medizin (Heidelberg, Germany)|June 30, 2025
[Monoclonal antibodies in patients with chronic inflammatory bowel diseases]Elisabeth Schnoy, Sirka Nitschmann
Biomedicines|June 26, 2025
Malignancy and Inflammatory Bowel Disease (IBD): Incidence and Prevalence of Malignancy in Correlation to IBD Therapy and Disease Activity-A Retrospective Cohort Analysis over 5 YearsAgnieszka Jowita Kafel, Anna Muzalyova, Elisabeth Schnoy
Zeitschrift Fur Gastroenterologie|June 16, 2025
From guidelines to evidence-based practice - A German perspective on mesalazine as first-line therapy for mild-to-moderate ulcerative colitisElisabeth Schnoy, Axel Dignass, Matthew Gaskins, et al.
Zeitschrift Fur Gastroenterologie|March 13, 2026
Correction: From guidelines to evidence-based practice - A German perspective on mesalazine as first-line therapy for mild-to-moderate ulcerative colitisElisabeth Schnoy, Axel Dignass, Matthew Gaskins, et al.
Zeitschrift Fur Gastroenterologie|June 22, 2026
[Version 7.0 of the S3 Guideline on Ulcerative Colitis sets out clearly defined treatment goals, an open treatment sequence, and a call for improved cross-sectoral care]Irina Blumenstein, Axel Dignass, Torsten Kucharzik, et al.
World Journal of Gastroenterology|September 19, 2014
Smoking increases the risk of extraintestinal manifestations in Crohn's diseaseClaudia Ott, Angela Takses, Florian Obermeier, et al.
Deutsche Medizinische Wochenschrift (1946)|March 31, 2025
[Advanced therapies: Un update on medical treamtent options in Crohn`s disease]Agnieszka Kafel, Clara Rodriguez de Castro Zalona, Chiara Seiz, et al.
United European Gastroenterology Journal|March 8, 2018
Suitability of the simplified autoimmune hepatitis score for the diagnosis of autoimmune hepatitis in a German cohortHella Wobser, Tanja Paur, Elisabeth Schnoy, et al.
International Journal of Colorectal Disease|September 3, 2014
How fast up the ladder? Factors associated with immunosuppressive or anti-TNF therapies in IBD patients at early stages: results from a population-based cohortClaudia Ott, Angela Takses, Florian Obermeier, et al.
Digestive Diseases (Basel, Switzerland)|December 1, 2024
Antibody Response to SARS-CoV-2 before and after the Third Vaccination in Patients with Inflammatory Bowel DiseaseJohanna Maria Classen, Anna Muzalyova, Christoph Römmele, et al.
Pageof 4

Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
Innere Medizin (Heidelberg, Germany)|June 30, 2025
[Monoclonal antibodies in patients with chronic inflammatory bowel diseases]Elisabeth Schnoy, Sirka Nitschmann
Biomedicines|June 26, 2025
Malignancy and Inflammatory Bowel Disease (IBD): Incidence and Prevalence of Malignancy in Correlation to IBD Therapy and Disease Activity-A Retrospective Cohort Analysis over 5 YearsAgnieszka Jowita Kafel, Anna Muzalyova, Elisabeth Schnoy
Zeitschrift Fur Gastroenterologie|June 16, 2025
From guidelines to evidence-based practice - A German perspective on mesalazine as first-line therapy for mild-to-moderate ulcerative colitisElisabeth Schnoy, Axel Dignass, Matthew Gaskins, et al.
Zeitschrift Fur Gastroenterologie|March 13, 2026
Correction: From guidelines to evidence-based practice - A German perspective on mesalazine as first-line therapy for mild-to-moderate ulcerative colitisElisabeth Schnoy, Axel Dignass, Matthew Gaskins, et al.
Zeitschrift Fur Gastroenterologie|June 22, 2026
[Version 7.0 of the S3 Guideline on Ulcerative Colitis sets out clearly defined treatment goals, an open treatment sequence, and a call for improved cross-sectoral care]Irina Blumenstein, Axel Dignass, Torsten Kucharzik, et al.
World Journal of Gastroenterology|September 19, 2014
Smoking increases the risk of extraintestinal manifestations in Crohn's diseaseClaudia Ott, Angela Takses, Florian Obermeier, et al.
Deutsche Medizinische Wochenschrift (1946)|March 31, 2025
[Advanced therapies: Un update on medical treamtent options in Crohn`s disease]Agnieszka Kafel, Clara Rodriguez de Castro Zalona, Chiara Seiz, et al.
United European Gastroenterology Journal|March 8, 2018
Suitability of the simplified autoimmune hepatitis score for the diagnosis of autoimmune hepatitis in a German cohortHella Wobser, Tanja Paur, Elisabeth Schnoy, et al.
International Journal of Colorectal Disease|September 3, 2014
How fast up the ladder? Factors associated with immunosuppressive or anti-TNF therapies in IBD patients at early stages: results from a population-based cohortClaudia Ott, Angela Takses, Florian Obermeier, et al.
Digestive Diseases (Basel, Switzerland)|December 1, 2024
Antibody Response to SARS-CoV-2 before and after the Third Vaccination in Patients with Inflammatory Bowel DiseaseJohanna Maria Classen, Anna Muzalyova, Christoph Römmele, et al.
Pageof 4